Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers.

Cancers (Basel)

International Clinical Research Center, St. Anne's University Hospital, 656 91 Brno, Czech Republic.

Published: May 2019

Gastrointestinal cancers (GC) are malignancies involving the gastrointestinal (GI) tract and accessory organs of the digestive system, including the pancreas, liver, and gall bladder. GC is one of the most common cancers and contributes to more cancer-related deaths than cancers of any other system in the human body. Causative factors of GC have been consistently attributed to infections, smoking, an unhealthy diet, obesity, diabetes, and genetic factors. More recently, aberrant epigenetic regulation of gene expression has emerged as a new, fundamental pathway in GC pathogenesis. In this review, we summarize the role of the macroH2A histone family in GI cell function and malignant transformation, and highlight how this histone family may open up novel biomarkers for cancer detection, prediction, and response to treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562817PMC
http://dx.doi.org/10.3390/cancers11050676DOI Listing

Publication Analysis

Top Keywords

gastrointestinal cancers
8
histone family
8
macro histone
4
histone variants
4
variants emerging
4
emerging rheostats
4
rheostats gastrointestinal
4
cancers
4
cancers gastrointestinal
4
cancers malignancies
4

Similar Publications

Retroperitoneal lymphangioma is exceptionally rare. We present a case of a 41-year-old asymptomatic patient with a large abdominal cystic mass detected on contrast-enhanced computed tomography (CT) scan, initially suspected to be pseudomyxoma peritonei. Laparoscopic exploration revealed a 30 x 30 cm multilocular cystic tumour originating from the retroperitoneum.

View Article and Find Full Text PDF

Epidemiology and anatomic distribution of colorectal cancer in South Africa.

S Afr J Surg

December 2024

Centre for Global Surgery, Department of Global Health, Stellenbosch University, South Africa.

Background: Colorectal cancer (CRC) is the fifth most common cancer in sub-Saharan Africa (SSA) and the third most common in South Africa (SA). CRC characteristics in SSA are not well described. The aim is to describe patient characteristics and anatomic location of colorectal adenocarcinoma (CRC-AC) in SA.

View Article and Find Full Text PDF

Objective: Fluoropyrimidine chemotherapy is a first-line treatment for many gastrointestinal (GI) cancers, however, cardiotoxicity concerns may limit administration in patients with pre-existing cardiovascular disease (CVD). This study investigated the association of pre-existing CVD with use of fluoropyrimidine chemotherapy in tumour-eligible GI cancer patients.

Methods And Analysis: National cancer registry data from the Virtual Cardio-Oncology Research Initiative from England between 2014 and 2018 was used to identify GI cancer patients eligible to receive fluoropyrimidine chemotherapy.

View Article and Find Full Text PDF

Objective: To evaluate the safety profiles of EZH2-targeted inhibitors in cancer treatment, focusing on treatment-related adverse events (TRAEs) across various clinical trials.

Methods: We conducted a systematic review and meta-analysis using data from clinical trials involving EZH2 inhibitors reported up to May 31, 2024. Databases searched included PubMed, Embase, CENTRAL (Cochrane Central Register of Controlled Trials), and ClinicalTrials.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) have transformed oncological treatment by modulating immune responses against tumors. However, their efficacy is subject to inter-patient variability and is associated with immune-related adverse events (irAEs). The human gut microbiota, a complex microbial ecosystem, is increasingly implicated in modulating responses to ICIs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!